Search Videos and More
PARP-1 inhibitors can reduce ovarian cancer recurrence risk by 70% in half of patients
UT Southwestern is leading research to find ways to extend the benefits of PARP-1 inhibitor maintenance medication to more patients with more forms of ovarian cancer.History of Vaccines Offers Lessons on COVID-19 for Pregnant Women
Emily H. Adhikari, M.D., and Catherine Y. Spong, M.D., describe how the available safety and effectiveness data, basic science of mRNA vaccines, and long history of successful administering of other vaccines in pregnant women